GLP-1 Receptor Agonists vs Alternatives for Alcohol Use Disorder: A Multi-Target Trial Emulation
Rodriguez, P. J.; Lusk, J. B.; Mehta, H. B.; Levy, J. F.; Kalogeropoulos, A.; Soneji, S.; Webber, E.; Gluckman, T. J.; Stucky, N.
Show abstract
BackgroundGlucagon-like peptide 1 receptor agonists (GLP-1 RAs) have shown promise for alcohol use disorder (AUD). ObjectiveTo evaluate the association between use of newer GLP-1 RAs (semaglutide, tirzepatide) and alcohol-related hospitalizations among adults with AUD and either type 2 diabetes (T2D) or obesity. MethodsThis retrospective target trial emulation study used electronic health record data from Truveta to identify adults with AUD and either T2D or obesity, who initiated a newer GLP-1 RA (semaglutide, tirzepatide) or relevant active comparator between 2018 and 2024. Four target trials were constructed to reflect clinically distinct populations and comparators: (1) ADM trial (patients with T2D and comparators of other anti-diabetic medications [ADM]), (2) AOM trial (patients with obesity but not T2D and comparators of other anti-obesity medications [AOM]), (3) MAUD-T2D trial (patients with T2D and markers of more severe AUD and comparators of medications for alcohol use disorder [MAUD]), (4) MAUD-obesity trial (patients with obesity, no T2D, and markers of more severe AUD and comparators of MAUD). The primary endpoint was time to alcohol-related hospitalization. Non-alcohol-related hospitalization served as a negative control outcome. Propensity score-based methods (weighting and matching) were used to control for confounding. Cox proportional hazards models were used to estimate the treatment effect of newer GLP-1 RA in four target trials. ResultsA total of 40,260 patients were identified, including 18,515 in the ADM trial, 9,256 in the AOM trial, 9,975 in the MAUD and T2D trial, and 11,039 in the MAUD and obesity trial. GLP-1 RAs were associated with a lower hazard of alcohol-related hospitalization in the ADM (HR [95% CI]: 0.70 [0.59 - 0.83] vs. sulfonylureas; 0.73 [0.62 - 0.86] vs. other ADMs), AOM (HR: 0.59 [0.48 - 0.74]), MAUD-T2D (HR: 0.36 [0.29 - 0.46]), and MAUD-obesity (HR: 0.32 [0.23 - 0.43]) trials. No significant differences were observed for non-alcohol-related hospitalizations for ADM and MAUD-T2D trials. ConclusionNewer GLP-1 RAs were associated with reduced risk of alcohol-related hospitalization across clinically distinct populations.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Specific diagnostic criteria identify those at high risk for progression from ‘preaddiction’ to severe alcohol use disorder 92%
- Neuroanatomical variability associated with early substance use initiation: Results from the ABCD Study 88%
- Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical Trial 88%
Similar papers in this journal
- Association of Topiramate Prescribed for any Indication with Reduced Alcohol Consumption in Electronic Health Record Data 94%
- Moderators of changes in smoking, drinking, and quitting behaviour associated with the first Covid-19 lockdown in England 89%
- Concurrent validity of an Estimator of Weekly Alcohol Consumption (EWAC) based on the Extended AUDIT 89%
Similar papers in this journal
Similar papers in this journal
- Genetic underpinnings of the transition from alcohol consumption to alcohol use disorder: shared and unique genetic architectures in a cross-ancestry sample 90%
- Multivariate GWAS elucidates the genetic architecture of alcohol consumption and misuse, corrects biases, and reveals novel associations with disease 90%
- Genetic Heterogeneity Across Dimensions of Alcohol Use Behaviors 89%
Similar papers in this journal
- Genetic liability for substance use associated with medical comorbidities in electronic health records of African- and European-ancestry individuals 92%
- Neurogenetic and multi-omic sources of overlap among sensation seeking, alcohol consumption, and alcohol use disorder 91%
- Enhancement of alcohol aversion by the nicotinic acetylcholine receptor drug sazetidine-A 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.